Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.

Inclusion Criteria

Patients must be 18 years of age or older at the time of enrollment
High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).

Exclusion Criteria

Patients who are pregnant or lactating.
Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04816526.

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationCartesian Therapeutics

Primary IDDC-08-B
Secondary IDsNCI-2022-00440
ClinicalTrials.gov IDNCT04816526

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Inclusion Criteria

Exclusion Criteria

Have a question?
We're here to help

Which trials are right for you?

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help